Regarding GC, although many biomarkers have been reported, CEACAM5 is the most frequently used in clinical practice and shows promising potential for the development of possible fluorescent molecules against this target [58,59,60,61,62]. The gene discussed is CEACAM5; the disease is gastric cancer.